Although many studies have highlighted the role of gamma-aminobutyric acid (GABA) in the pathophysiology of psychosis, there is no drug-induced animal model in which GABA is manipulated. In this article we propose a hypothetical animal model for psychosis based on the silencing GABAergic system. The presentation also suggest Pre-Pulse Inhibition test as a preferred approach towards proving this hypothesis.
Gelder, Michael G, Richard Mayou, John Geddes. Psychiatry. New York: Oxford University Press; 2005.
Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: A critical review. Journal of Psychiatry Neuroscience. 2001; 26(5):395-410. PMID: 11762207
Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research. 2005; 79(1):59-68. doi: 10.1016/j.schres.2005.01.003
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Current Pharmaceutical Design. 2009; 15(22):2550-9. doi: 10.2174/138161209788957528
Riederer P, Lange KW, Kornhuber J, Danielczyk W. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung. 1992; 42(2A):265-8. doi: PMID: 1350197
Halberstadt AL. The Phencyclidine-glutamate model of schizophrenia.Clinical Neuropharmacology. 1995; 18(3):237-49. doi: 10.1097/00002826-199506000-00004
Kang JI, Park HJ, Kim SJ, Kim KR, Lee SY, Lee E, et al. Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: An [18F]-fluoroflumazenil positron emission tomography study. Schizophrenia Bulletin. 2014; 40(3):548-57. doi: 10.1093/schbul/sbt052
Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, et al. GABAergic dysfunction in schizophrenia: New treatment strategies on the horizon. Psychopharmacology. 2005; 180(2):191-205. doi: 10.1007/s00213-005-2212-8
Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, et al. A GABAergic cortical deficit dominates schizophrenia pathophysiology. Critical Reviews in Neurobiology. 2004; 16(1-2):1-23. doi: PMID: 15581395
Wieronska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A. The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. British Journal of Pharmacology. 2011; 163(5):1034-47. doi: 10.1111/j.1476-5381.2011.01301.x
Lavielle S, Tassin JP, Thierry AM, Blanc G, Herve D, Barthelemy C, et al. Blockade by benzodiazepines of the selective high increase in dopamine turnover induced by stress in mesocortical dopaminergic neurons of the rat. Brain Research. 1979;168(3):585-94. doi: 10.1016/0006-8993(79)90311-1
Fadda P, Scherma M, Fresu A, Collu M, Fratta W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003; 50(1):1-6. doi: 10.1002/syn.10238
Kurup RK, Kurup PA. Endogenous strychnine: description of hypoand hyperstrychninergic state in relation to neuropsychiatric diseases. International Journal of Neuroscience 2002; 2(10):1229â41. doi: 10.1080/00207450290026175
Garbutt JC, van Kammen DP. The interaction between GABA and dopamine: Implications for schizophrenia. Schizophrenia bulletin. 1983; 9(3):336-53. doi: 10.1093/schbul/9.3.336
Geyer MA, Moghaddam B. Animal models relevant to schizophrenia disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff Ch, editors. Neuropsychopharmacology: The fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins; 2002.
Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. A Survey of Cell Biology. 2002; 213:1-47. doi: 10.1016/s0074-7696(02)13011-7
Mena A, Ruiz-Salas JC, Puentes A, Dorado I, Ruiz-Veguilla M, De la Casa LG. Reduced prepulse inhibition as a biomarker of schizophrenia. Frontiers in Behavioral Neuroscience. 2016; 10:202. doi: 10.3389/fnbeh.2016.00202
Dehghani, R. & Shahbazi, A. (2016). A Hypothetical Animal Model for Psychosis Based on the Silencing of GABAergic System. Journal of Advanced Medical Sciences and Applied Technologies, 2(4), 321–322. https://doi.org/10.18869/nrip.jamsat.2.4.321
MLA
Dehghani, R., & Shahbazi, A. "A Hypothetical Animal Model for Psychosis Based on the Silencing of GABAergic System", Journal of Advanced Medical Sciences and Applied Technologies, 2, 4, 2016, 321–322. doi: 10.18869/nrip.jamsat.2.4.321
HARVARD
Dehghani, R., & Shahbazi, A. (2016). 'A Hypothetical Animal Model for Psychosis Based on the Silencing of GABAergic System', Journal of Advanced Medical Sciences and Applied Technologies, 2(4), pp. 321–322. doi: 10.18869/nrip.jamsat.2.4.321
CHICAGO
Dehghani, R. & Shahbazi, A., "A Hypothetical Animal Model for Psychosis Based on the Silencing of GABAergic System." Journal of Advanced Medical Sciences and Applied Technologies, 2 4 (2016): 321–322, doi: 10.18869/nrip.jamsat.2.4.321
VANCOUVER
Dehghani R., Shahbazi A. A Hypothetical Animal Model for Psychosis Based on the Silencing of GABAergic System. JAMSAT. 2016;2(4):321–322. doi: 10.18869/nrip.jamsat.2.4.321
